Efficacy and safety of subcutaneous infliximab versus adalimumab etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis
- Title
- Efficacy and safety of subcutaneous infliximab versus adalimumab etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis
- Author
- 유대현
- Keywords
- Adalimumab; biosimilar; CT-P13; etanercept; infliximab; rheumatoid arthritis
- Issue Date
- 2021-01
- Publisher
- TAYLOR & FRANCIS LTD
- Citation
- EXPERT REVIEW OF CLINICAL IMMUNOLOGY, v. 17, no. 1, page. 85-99
- Abstract
- Objectives: There are few comparative data for tumor necrosis factor inhibitors in patients with rheumatoid arthritis (RA).
Methods: Historical data for reference product/biosimilar intravenous infliximab, or adalimumab and etanercept, were pooled and compared with phase 3 study results for a subcutaneous (SC) formulation of the infliximab biosimilar CT-P13, in a systematic review and meta-analysis (PROSPERO: CRD42019149621).
Results: The authors identified 13 eligible controlled trials that randomized over 5400 participants to prespecified treatments of interest. Comparison with pooled historical data suggested a numerical advantage for CT-P13 SC over intravenous infliximab for almost every prespecified efficacy outcome evaluated, including Disease Activity Score in 28 joints (C-reactive protein/erythrocyte sedimentation rate), Clinical/Simplified Disease Activity Index scores, American College of Rheumatology responses, and multiple measures of disease remission and low disease activity; for the majority of outcomes, there was no overlap in 95% confidence intervals between groups. A numerical advantage for CT-P13 SC was also observed for safety outcomes (adverse events, infections, and discontinuations). Similar, but less marked, trends were observed for comparison with historical efficacy and safety data for adalimumab/etanercept.
Conclusion: CT-P13 SC offers an improved or similar benefit-to-harm ratio compared with infliximab (intravenous) and adalimumab/etanercept, for the treatment of moderate-to-severe RA.
- URI
- https://www.tandfonline.com/doi/full/10.1080/1744666X.2020.1858803https://repository.hanyang.ac.kr/handle/20.500.11754/175385
- ISSN
- 1744-666X; 1744-8409
- DOI
- 10.1080/1744666X.2020.1858803
- Appears in Collections:
- COLLEGE OF MEDICINE[S](의과대학) > MEDICINE(의학과) > Articles
- Files in This Item:
- Efficacy and safety of subcutaneous infliximab versus adalimumab etanercept and intravenous infliximab in patients with rheumatoid arthritis a syst...Download
- Export
- RIS (EndNote)
- XLS (Excel)
- XML